News headlines about Repligen (NASDAQ:RGEN) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repligen earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8801567562351 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Repligen (RGEN) opened at $36.08 on Friday. The company has a market capitalization of $1,534.81, a PE ratio of 60.74, a PEG ratio of 2.30 and a beta of 1.04. Repligen has a 1 year low of $28.48 and a 1 year high of $46.81.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.11 by $0.04. The firm had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company’s revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.08 EPS. equities analysts expect that Repligen will post 0.61 EPS for the current year.
A number of equities analysts have weighed in on RGEN shares. Jefferies Group restated a “hold” rating and issued a $40.00 target price on shares of Repligen in a research note on Thursday, September 14th. Stephens reiterated an “overweight” rating and set a $50.00 price objective on shares of Repligen in a research report on Tuesday, September 26th. First Analysis upgraded Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective on the stock in a research report on Monday, October 2nd. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research report on Thursday, October 5th. Finally, CL King initiated coverage on Repligen in a research report on Monday, November 13th. They set a “buy” rating and a $41.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Repligen has an average rating of “Buy” and an average price target of $44.38.
WARNING: This report was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://ledgergazette.com/2017/12/17/repligen-rgen-receives-daily-news-sentiment-rating-of-0-13.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.